About Dr. Sun Yongwei
Dr. Sun Yongwei (孙勇伟) is the Deputy Director of the Department of Hepatobiliary and Pancreatic Surgery at Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. He is one of Shanghai's leading specialists in the treatment of locally advanced and metastatic pancreatic cancer, with particular expertise in conversion therapy, neoadjuvant strategies, and pancreatic neuroendocrine tumors (pNETs).
Dr. Sun's clinical focus addresses one of the most pressing challenges in pancreatic oncology: how to give patients with initially unresectable disease a genuine chance at surgery. Through carefully designed neoadjuvant chemotherapy and conversion therapy protocols, his team has helped a meaningful proportion of patients with locally advanced or borderline resectable pancreatic cancer achieve surgical resection — and with it, the possibility of long-term survival.
Clinical Expertise
- Conversion therapy for locally advanced pancreatic cancer — systemic chemotherapy and/or radiotherapy designed to shrink tumors and convert unresectable disease to a surgically resectable state
- Neoadjuvant strategies for borderline resectable pancreatic cancer — pre-operative treatment to improve R0 resection rates and reduce the risk of early recurrence
- Metastatic pancreatic cancer management — palliative and life-prolonging systemic therapy including FOLFIRINOX, gemcitabine-based regimens, targeted agents, and immunotherapy combinations
- Pancreatic neuroendocrine tumors (pNETs) — surgical and medical management of functional and non-functional pNETs, including somatostatin analogues, PRRT (peptide receptor radionuclide therapy), and everolimus/sunitinib
- Pancreatic surgery — pancreaticoduodenectomy, distal pancreatectomy, and minimally invasive resections for resectable disease
- Multidisciplinary tumor board coordination — integrating hepatobiliary surgery, medical oncology, interventional radiology, and nuclear medicine for complex case management
Why Dr. Sun Yongwei?
For patients diagnosed with locally advanced or metastatic pancreatic cancer — often told that surgery is not an option — Dr. Sun's expertise in conversion therapy offers a critical second pathway. His approach combines aggressive systemic treatment with careful surgical reassessment, giving patients who respond to chemotherapy the opportunity to proceed to curative-intent resection.
His specialization in pancreatic neuroendocrine tumors also fills an important niche: pNETs are biologically distinct from pancreatic ductal adenocarcinoma and require a different treatment philosophy. Dr. Sun's experience with the full spectrum of pNET management — from surveillance of small incidental tumors to complex resections and systemic therapy for metastatic disease — makes him a valuable resource for international patients with this diagnosis.
Renji Hospital's hepatobiliary and pancreatic surgery department is one of the busiest in Shanghai, with a high volume of complex referral cases and a strong track record in both surgical outcomes and systemic therapy coordination.
Hospital: Renji Hospital, Shanghai Jiao Tong University School of Medicine
Renji Hospital is one of Shanghai's premier academic medical centers, with a history spanning over 160 years. Affiliated with Shanghai Jiao Tong University School of Medicine, it is consistently ranked among China's top hospitals and is internationally recognized for its hepatobiliary, oncology, and transplant programs. The hospital operates a dedicated hepatopancreatobiliary (HPB) center with multidisciplinary tumor boards, advanced interventional radiology, and a nuclear medicine department capable of delivering PRRT for neuroendocrine tumors.
About Locally Advanced & Metastatic Pancreatic Cancer
Approximately 80–85% of pancreatic cancer patients present with locally advanced or metastatic disease at diagnosis, making them ineligible for immediate surgery. However, advances in systemic therapy have changed the landscape significantly:
- Conversion therapy success rates: 15–30% of locally advanced patients who respond to neoadjuvant chemotherapy can ultimately undergo surgical resection
- FOLFIRINOX (oxaliplatin + irinotecan + fluorouracil + leucovorin) remains the most effective first-line regimen for fit patients with locally advanced disease
- Gemcitabine + nab-paclitaxel is an alternative for patients who cannot tolerate FOLFIRINOX, with a favorable toxicity profile
- PARP inhibitors (olaparib) are approved for maintenance therapy in BRCA1/2-mutated pancreatic cancer after platinum-based chemotherapy
- KRAS inhibitors (targeting G12C and G12D mutations) represent an emerging frontier, with clinical trials ongoing
- Pancreatic neuroendocrine tumors (pNETs) have a significantly better prognosis — 5-year survival rates of 50–70% even with metastatic disease — and respond to somatostatin analogues, targeted therapy, and PRRT
What to Prepare Before Your Consultation
To enable Dr. Sun's team to conduct a thorough remote case review, international patients should prepare:
- CT scan of the abdomen and pelvis with contrast (DICOM format, within 3 months)
- PET-CT scan if available (particularly useful for staging and neuroendocrine tumors)
- Pathology report and biopsy results, including immunohistochemistry (Ki-67 index for pNETs)
- CA 19-9, CEA, chromogranin A (for pNETs), and other relevant tumor markers
- Summary of prior chemotherapy regimens with response assessments (CT or PET response)
- Genetic testing results (BRCA1/2, PALB2, MSI/MMR, KRAS mutation status)
- Current performance status and nutritional assessment
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Dr. Sun Yongwei and the Renji Hospital hepatobiliary and pancreatic surgery team for international patients. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Dr. Sun's team
- Full translation of medical records, imaging reports, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 commenti